Search

everythinglearnresearchcommunity

for

Search:↓

2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.

Tripterygium wilfordii multiglycoside effectively reduced prostate enlargement in rats without harmful effects.

Finasteride treats hair loss but may affect prostate cancer detection.

The healthcare for transgender veterans could be better with a more unified team approach.

There's no link between hair loss type androgenic alopecia and benign prostatic hyperplasia, but early hair loss and family history can mean more severe alopecia.

Doxazosin alone or combined with finasteride improves prostate symptoms better than finasteride alone, without extra benefits.

Higher testosterone and DHT levels are linked to hair loss in men, but not to prostate cancer risk.

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

Trichoscopy helps tell different hair loss types apart using specific scalp and hair patterns.

Upadacitinib effectively treated a patient with multiple inflammatory conditions.

A young man with high-grade prostate cancer had successful surgery and good recovery, highlighting the need for awareness in younger men.

Trapa bispinosa Roxb. extract may help reduce prostate size and cell growth in BPH.

Correct testosterone levels for age to treat prostate cancer, using low dose treatments as necessary.

Low testosterone does not prevent prostate cancer in men with type 1 diabetes.

The conclusion is that women are heavily affected by autoimmune skin diseases, face significant challenges, and need better research, treatments, and healthcare policies.

Baldness (androgenic alopecia) could be a risk factor for prostate cancer.

After chemotherapy for early breast cancer, 33.4% of patients had long-term significant hair loss, with some hair regrowth over time, but treatments for hair loss were largely ineffective.

Higher CRP levels suggest chronic inflammation is linked to bladder-related urinary symptoms in men with enlarged prostates.

Early balding may be a sign of future prostate problems.

Patients with metabolic syndrome had lower Gleason scores when diagnosed with prostate cancer.

Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.

A higher genetic risk score increases the chance of getting benign prostatic hyperplasia and affects treatment outcomes in Han Chinese men.

Swedish men with the E213 A-allele of the androgen receptor have a lower risk of prostate cancer.

New treatments are making advanced prostate cancer management more complex but also more hopeful.

Larger prostate size in older men may be linked to poorer semen quality and fertility issues.

Surgery for high-risk prostate cancer is challenging but doesn't lead to more complications, and additional treatment is often needed.

Finasteride is effective for male hair loss, but it may cause fertility issues, mental health problems, and rarely, breast growth. Regular health checks can reduce the risk of prostate cancer. Patient understanding and involvement in treatment is important.

Higher serum androgens contribute to male pattern baldness.

Women with androgenetic alopecia (hair loss) have normal prostate specific antigen levels but higher testosterone levels.

Physalis peruviana extract is more effective in treating benign prostatic hyperplasia in rats than finasteride and terazosine.